Open Access Open Access  Restricted Access Subscription or Fee Access

Kratom and opioid use disorder in the perioperative period: A case report on the expanding role of buprenorphine

Josiah Perez, MD


Kratom (Mitragyna speciosa), an herbal plant gaining popularity as a treatment for chronic pain and opioid withdrawal symptoms, continues to be marketed and sold in the United States in an unregulated fashion. We present a patient with a history of opioid use disorder and taking kratom for chronic pain, who presented for an elective total knee replacement. We experienced challenges as well as successes with using buprenorphine as the primary medication to treat his post-operative pain, adding to the growing body of evidence to consider the use of buprenorphine both for kratom withdrawal and in the perioperative period.


kratom; buprenorphine; opioid use disorder; perioperative; post-operative pain

Full Text:



Bin AM: Kratom dependence and treatment options: A comprehensive review of the literature. Curr Drug Targets. 2020; 21(15): 1566-1579.

Kruegel AC, Gassaway MM, Kapoor A, et al.: Synthetic and receptor signaling explorations of the Mitragyna alkaloids: Mitragynine as an atypical molecular framework for opioid receptor modulators. J Am Chem Soc. 2016; 138(21): 6754-6764.

Veltri C, Grundmann O: Current perspectives on the impact of kratom use. Subst Abuse Rehabil. 2019; 10: 23-31.

Ismail I, Wahab S, Sidi H, et al.: Kratom and future treatment for the opioid addiction and chronic pain: Periculo beneficium? Curr Drug Targets. 2018; 20(2): 166-172.

White CM: Pharmacologic and clinical assessment of kratom. Am J Health Syst Pharm. 2018; 75(5): 261-267.

White CM: Pharmacologic and clinical assessment of kratom: An update. Am J Health Syst Pharm. 2019; 76(23): 1915-1925. Drug facts: Kratom. Available at Updated April 2019. Accessed January 29, 2021.

Schimmel J, Amioka E, Rockhill K, et al.: Prevalence and description of kratom (Mitragyna speciosa) use in the United States: A cross-sectional study. Addiction. 2021; 116(1): 176-181.

Buresh M: Treatment of kratom dependence with buprenorphine- naloxone maintenance. J Addict Med. 2018; 12(6): 481-483.

Khazaeli A, Jerry JM, Vazirian M: Treatment of kratom withdrawal and addiction with buprenorphine. J Addict Med. 2018; 12(6): 493-495.

Weiss ST, Douglas HE: Treatment of kratom withdrawal and dependence with buprenorphine/naloxone: A case series and systematic literature review. J Addict Med. 2021; 15(2): 167–172.

Vermaire DJ, Skaer D, Tippets W: Kratom and general anesthesia: A case report and review of the literature. A A Pract. 2019; 12(4): 103-105.

Cauley CE, Anderson G, Haynes AB, et al.: Predictors of in-hospital postoperative opioid overdose after major elective operations: A nationally representative cohort study. Ann Surg. 2017; 265(4): 702-708.

Goel A, Azargive S, Weissman JS, et al.: Perioperative pain and addiction interdisciplinary network (PAIN) clinical practice advisory for perioperative management of buprenorphine: Results of a modified Delphi process. Br J Anaesth. 2019; 123(2): e333-e342.

Li AH, Schmiesing C, Aggarwal AK: Evidence for continuing buprenorphine in the perioperative period. Clin J Pain. 2020; 36(10): 764-774.



  • There are currently no refbacks.